Balchem reported third-quarter sales of US$290.7 million and net earnings of US$46.7 million in its 23 October 2026 results. Reported diluted earnings per share increased to US$1.46 from US$1.24. Its separate adjusted figure was US$1.57, versus US$1.35 a year earlier.
The disclosed amounts
| Measure | Disclosure | Official evidence |
|---|---|---|
| Net sales | US$290.7 million; the financial table lists US$290.658 million, versus US$267.558 million in Q3 2025. | Source document |
| Reported net earnings | US$46.7 million; the table lists US$46.728 million, versus US$40.289 million. | Source document |
| Reported diluted EPS | US$1.46, versus US$1.24 in Q3 2025. | Source document |
| Adjusted diluted EPS, non-GAAP | US$1.57, versus US$1.35 in Q3 2025. | Source document |
| Adjusted EBITDA, non-GAAP | US$80.3 million. | Source document |
| Cash generation | Operating cash flow US$69.8 million; free cash flow US$57.9 million. | Source document |
A source discrepancy worth keeping visible
At the recorded source check, Balchem’s HTML summary listed growth of 6% for sales, 0% for net earnings and 4% for adjusted EBITDA. The linked official PDF instead stated 8.6%, 16.0% and 12.4%, with a financial table consistent with those PDF percentages. This report uses the disclosed amounts and per-share figures, not the conflicting growth-rate labels.
The discrepancy is not evidence that the figures are zero or that a correction has already been issued. Readers should consult the exact PDF table and any later issuer clarification rather than assume the web summary and document are identical.
Reported versus adjusted
Reported earnings follow GAAP accounting rules. Balchem’s adjusted earnings and adjusted EBITDA remove specified items under its non-GAAP reconciliation, so neither should replace the reported result. EBITDA is earnings before interest, tax, depreciation and amortisation; adjusted EBITDA applies additional exclusions.
Cash flow answers a different question from profit. Operating cash flow records cash generated by operations, while free cash flow is operating cash flow minus capital expenditure, net of proceeds from asset sales. The current report covers one quarter, not the full nine months shown elsewhere in the tables.
Official evidence and scope
Primary official record and official companion record. These are the same issuer’s PDF and HTML summary. Their growth-rate labels conflict as disclosed above; no independent human audit or resolution of that discrepancy is claimed. Latest saved source observation: . This report does not establish a live share-price reaction or an investment return.
Related CapKet coverage: Colgate India’s separately reported sales, profit and dividend timetable.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.